• In early June 2026, Amgen reported that the European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) in extensive-stage small cell lung cancer, while new Phase 3 and real-world data for UPLIZNA and TAVNEOS at EULAR 2026 supported their longer-term safety and disease-control profiles in rare autoimmune conditions.
• Together, these updates underscore Amgen’s focus on high unmet-need niches, where differentiated mechanisms and maturing evidence can be especially influential for clinicians and regulators.
• We’ll now examine how IMDYLLTRA’s European approval, alongside strengthened rare-disease data, may influence Amgen’s broader investment narrative.

Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

Amgen Investment Narrative Recap

To own Amgen, you need to believe that its late stage pipeline and recent acquisitions can more than offset pricing pressure, biosimilar erosion, and rising R&D and manufacturing spend. IMDYLLTRA’s EU approval and the new UPLIZNA and TAVNEOS data reinforce that pipeline story, but they do not change the near term reality that drug pricing reform and biosimilar competition remain the most important catalyst and risk to watch.

Among the recent updates, the European authorization of IMDYLLTRA stands out as most relevant. It reinforces Amgen’s efforts in oncology at the same time analysts are focused on how newer products can counterbalance patent expirations and biosimilar pressure. IMDYLLTRA’s Phase 3 survival benefit in extensive stage small cell lung cancer feeds directly into that debate about whether emerging therapies can support revenue and earnings resilience.

Yet even with fresh approvals and data, investors should be aware that intensifying drug pricing reforms could still...

Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029. This requires 2.5% yearly revenue growth and about a $2.1 billion earnings increase from $7.8 billion today.

Uncover how Amgen's forecasts yield a $352.23 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming Amgen’s revenue would stay near US$36.7 billion and earnings around US$7.6 billion, so this kind of oncology and rare disease progress may challenge that more pessimistic view and is exactly why you should compare different scenarios before deciding what you believe about Amgen’s future.

Explore 4 other fair value estimates on Amgen - why the stock might be worth just $352.23!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.